Balaji Telefilms Partners with YouTube to Launch 5 Premium Shows
"Balaji Telefilms and YouTube will collaborate to create and distribute premium content for a growing digital and Connected TV audience."
Balaji Telefilms Enters Strategic Partnership with YouTube
Balaji Telefilms Ltd. has announced a strategic partnership with YouTube to develop and distribute a slate of premium digital shows.
Under the partnership, five exclusive shows with around 200 episodes will be created, bringing together Balaji Telefilms' content expertise and YouTube's distribution and monetisation capabilities. The shows will be produced in 4K and made available to audiences globally.
Partnership Details
- Partners: Balaji Telefilms and YouTube.
- Content: 5 exclusive premium shows comprising around 200 episodes.
- Creative Lead: Ekta Kapoor will lead the creative vision for the projects.
- Intellectual Property: Balaji Telefilms will retain the IP for the shows.
- Distribution: YouTube will support global distribution and monetisation through advertising and brand partnerships.
Upcoming Shows
The partnership's content slate includes popular titles and new programming, including:
- Haq Se – Season 2
- Phir Pyar Ki Yeh Kahani Suno
- Kehne Ko Humsafar Hai – Season 4
What to Watch Next
Investors may track the launch schedule and audience response to the upcoming shows, along with the monetisation generated through advertising and brand partnerships. The performance of the new content slate could provide further visibility into Balaji Telefilms' digital expansion strategy.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Bajaj Nivesh Reports 9.7% Revenue Growth in Q2 FY27, Net Profit Rises 9.8%
Bajaj Nivesh Limited has reported its financial results for the quarter and half year ended September 30, 2026. The company recorded revenue from operations of Rs.297.36 crore in Q2 FY27, up 9.7% year-on-year (YoY). Net profit for the quarter stood at Rs.293.27 crore, while earnings per share increased to Rs.256.61 from Rs.233.69 in the corresponding quarter last year.
Balkrishna Industries Signs Strategic Partnership with Pirelli for Premium Car Tyres in India
Balkrishna Industries Limited (BKT) has signed a strategic agreement with Pirelli to expand its presence in India's premium passenger car tyre market. Under the agreement, BKT will produce up to 800,000 Pirelli-branded premium car tyres by 2030. Production will take place at one of BKT's newly constructed plants, equipped with advanced technology and designed to meet Pirelli's quality standards. The agreement also provides for a potential 50-50 joint venture to build a new production plant for high-value car tyres for domestic and international markets. The partnership aims to help both companies benefit from the expected growth in India's premium car tyre market.
Corona Remedies Receives ANVISA GMP Certification for Two Manufacturing Facilities
Corona Remedies Limited has received Good Manufacturing Practice (GMP) Compliance Certification from Brazil’s Health Regulatory Agency, ANVISA, for its Oral Solid Dosage (OSD) manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad, Gujarat. The company disclosed the development to BSE Limited and the National Stock Exchange of India Limited on October 22, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The certification may support the company's efforts to expand its presence in international pharmaceutical markets, subject to applicable regulatory requirements.